Abstract:Population density and immune status, vectors and virulence of infection, nutritional status, sanitation, genetic susceptibility and medical management of cases, are important factors influencing the incidence and/or severity of virus infections. Thus, the prevalence and clinical importance of virus infections and the need for antiviral drugs differ from place to place and from time to time. National and World Health Statistics of notifications of disease give some index of the incidence of infections but not all virus infections are notifiable. Such statistics can be misleading also through failures to notify from sloth on the part of the physician or, in the absence of pathognomonic symptoms or signs, from errors in diagnosis. Any assessment of the need for new antiviral drugs should consider the availability, safety, effectiveness and cost of alternative measures, including prevention of spread of infection by control of vectors, immunization by use of viral vaccines, or treatment with existing antiviral drugs. Early start of treatment of acute virus infections with existing drugs gives the best results and, where the clinical diagnosis is uncertain, accurate rapid virus diagnosis is of paramount importance. Many virus infections are asymptomatic or of trivial importance and without sequelae. However, new or improved antiviral drugs are needed for the prevention and/or treatment of a number of significant conditions caused by viruses which are not at present adequately controlled. These include upper and lower respiratory tract infections, influenza, chronic hepatitis, gastroenteritis, infectious mononucleosis, measles, rabies, haemorrhagic fevers and warts. Furthermore, such drugs might prove of therapeutic value in the prevention or treatment of virus-associated tumours, such as hepatoma, nasopharyngeal carcinoma, Burkitt's lymphoma, Kaposi's sarcoma and possibly carcinoma of the cervix.

Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.

SARS-CoV-2: Mapping its features that made it as a unique virus

Vaccines against Coronaviruses: The State of the Art

Broad‐Spectrum Antiviral Peptides and Polymers

Anno 2021: Which antivirals for the coming decade?

Antivirals with common targets against highly pathogenic viruses

Engineering Antiviral Vaccines

The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design

Lessons learnt from broad-spectrum coronavirus antiviral drug discovery

COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective

Biosimilars as antivirals: opportunities and challenges

Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics

Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases

Broad-spectrum pan-genus and pan-family virus vaccines

The end of the beginning: vaccines for the next 25 years

The need for new antiviral agents

SARS-CoV-2: vaccines in the pandemic era

Nanostructures for Prevention, Diagnosis, and Treatment of Viral Respiratory Infections: from Influenza Virus to SARS-CoV-2 Variants

Pandemic preparedness: On the efficacy of non‐pharmaceutical interventions in COVID‐19 and about approaches to predict future pandemic viruses

A Game of Infection – Song of Respiratory Viruses and Interferons

New Challenges to Fighting COVID-19: Virus Variants, Potential Vaccines, and Development of Antivirals.